ZA200203431B - Therapeutic use. - Google Patents

Therapeutic use.

Info

Publication number
ZA200203431B
ZA200203431B ZA200203431A ZA200203431A ZA200203431B ZA 200203431 B ZA200203431 B ZA 200203431B ZA 200203431 A ZA200203431 A ZA 200203431A ZA 200203431 A ZA200203431 A ZA 200203431A ZA 200203431 B ZA200203431 B ZA 200203431B
Authority
ZA
South Africa
Prior art keywords
therapeutic use
patient
chemoprevention
onset
effective amount
Prior art date
Application number
ZA200203431A
Other languages
English (en)
Inventor
Bundred Nigel James
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of ZA200203431B publication Critical patent/ZA200203431B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200203431A 1999-11-02 2002-04-30 Therapeutic use. ZA200203431B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use

Publications (1)

Publication Number Publication Date
ZA200203431B true ZA200203431B (en) 2003-02-26

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203431A ZA200203431B (en) 1999-11-02 2002-04-30 Therapeutic use.

Country Status (21)

Country Link
US (1) US7553815B1 (xx)
EP (1) EP1272188B1 (xx)
JP (1) JP2003513035A (xx)
KR (1) KR100785359B1 (xx)
CN (1) CN1197577C (xx)
AT (1) ATE339957T1 (xx)
AU (1) AU779190B2 (xx)
BR (1) BR0015194A (xx)
CA (1) CA2389411C (xx)
CY (1) CY1106285T1 (xx)
DE (1) DE60030889T2 (xx)
DK (1) DK1272188T3 (xx)
ES (1) ES2275556T3 (xx)
GB (1) GB9925958D0 (xx)
IL (1) IL149176A0 (xx)
MX (1) MXPA02004272A (xx)
NO (1) NO323206B1 (xx)
NZ (1) NZ518696A (xx)
PT (1) PT1272188E (xx)
WO (1) WO2001032155A2 (xx)
ZA (1) ZA200203431B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE441433T1 (de) 2000-05-19 2009-09-15 Genentech Inc Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
WO2003037897A2 (en) * 2001-10-29 2003-05-08 Novartis Ag Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
EP1450799B2 (en) * 2001-12-03 2018-07-11 Bayer HealthCare LLC Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
PT1509230E (pt) * 2002-06-05 2007-03-30 Cedars Sinai Medical Center Gefitinib ( iressa ) para o tratamento do cancro
WO2005017493A2 (en) * 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarkers in cancer
US8318752B2 (en) 2003-09-19 2012-11-27 Astrazeneca Ab 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
EP2399605A1 (en) 2005-02-23 2011-12-28 Genentech, Inc. Extending time to disease progression or survival in cancer patients
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
NZ570381A (en) 2006-02-09 2011-02-25 Daiichi Sankyo Co Ltd Anti-cancer pharmaceutical composition
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN102421427B (zh) 2009-03-11 2013-11-06 阿迪生物科学公司 用于治疗特定癌症的包含rdea119/bay869766的药物组合
KR20130080871A (ko) 2009-03-20 2013-07-15 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
SI2536748T1 (sl) 2010-02-18 2014-12-31 Genentech, Inc. Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
BR112014024017A8 (pt) 2012-03-27 2017-07-25 Genentech Inc Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
CN104813168B (zh) 2012-11-30 2017-10-20 霍夫曼-拉罗奇有限公司 需要pd‑l1抑制剂综合疗法的患者的鉴定
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
DK0831829T3 (da) * 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
KR100437582B1 (ko) 1995-07-06 2004-12-17 노파르티스 아게 피롤로피리미딘및그들의제조방법
CA2332331A1 (en) * 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EP2059902B1 (en) 2006-08-28 2010-04-07 Koninklijke Philips Electronics N.V. Method and apparatus for image enhancement

Also Published As

Publication number Publication date
DK1272188T3 (da) 2007-01-29
ES2275556T3 (es) 2007-06-16
BR0015194A (pt) 2002-06-18
CN1197577C (zh) 2005-04-20
NO20022065D0 (no) 2002-04-30
IL149176A0 (en) 2002-11-10
EP1272188A2 (en) 2003-01-08
JP2003513035A (ja) 2003-04-08
CN1387437A (zh) 2002-12-25
EP1272188B1 (en) 2006-09-20
NZ518696A (en) 2004-12-24
GB9925958D0 (en) 1999-12-29
NO323206B1 (no) 2007-01-22
KR20020064306A (ko) 2002-08-07
CA2389411A1 (en) 2001-05-10
WO2001032155A3 (en) 2002-05-10
CA2389411C (en) 2009-09-01
AU1155901A (en) 2001-05-14
KR100785359B1 (ko) 2007-12-18
NO20022065L (no) 2002-06-24
ATE339957T1 (de) 2006-10-15
AU779190B2 (en) 2005-01-13
DE60030889T2 (de) 2007-04-05
MXPA02004272A (es) 2003-08-20
CY1106285T1 (el) 2011-10-12
DE60030889D1 (de) 2006-11-02
US7553815B1 (en) 2009-06-30
WO2001032155A2 (en) 2001-05-10
PT1272188E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
GB9925958D0 (en) Therapeutic use
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
EG25822A (en) Quinolinyl-pyrrolopyrazoles
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
MXPA00011248A (es) Tratamientos de tumores humanos con radiacion e inhibidores de tirosina cinasas de recptor de factor de crecimiento.
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
MY164077A (en) Compositions and uses of et743 for treating cancer
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
GB0020504D0 (en) Therapeutic method
AU5574001A (en) Method for treatment of tumors using photodynamic therapy
AU2001236529A1 (en) Combination therapy for cancer
MD1569G2 (ro) Metodă de tratament al cancerului mamar în perioada preoperatorie
IL159770A0 (en) Calcium salts with cytotoxic activity
CY1109852T1 (el) Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη
AU5434899A (en) Cancer treatment
AU2001240885A1 (en) Use of glucosylceramide synthesis inhibitors in brain cancer therapy
WO2000033823A3 (en) Methods of using temozolomide in the treatment of cancers
IL164092A0 (en) The use of devazepide as analgesic agent
UA28928A (uk) Спосіб лікування гнійно-запальних захворювань м'яких тканин
UA34376A (uk) Спосіб профілактики і корекції психосоматичних розладів у хворих при операціях з приводу рака молочної залози
MX9708340A (es) Mejoras en la profilaxis del cancer de mama, o relacionadas con esta.